NewAmsterdam Pharma Confirms Public Trading Registration

Ticker: NAMSW · Form: 8-K · Filed: Jan 22, 2024 · CIK: 1936258

Complexity: simple

Sentiment: neutral

Topics: compliance, regulatory-filing, corporate-governance

TL;DR

**NewAmsterdam Pharma just filed an 8-K confirming its shares and warrants are registered for public trading.**

AI Summary

NewAmsterdam Pharma Company N.V. filed an 8-K on January 22, 2024, primarily to disclose that its Ordinary Shares, with a nominal value of €0.12 per share, and Warrants to Purchase Ordinary Shares are registered for trading on an exchange. This filing, under Regulation FD, confirms the company's compliance with SEC reporting requirements and provides updated corporate information. For investors, this matters because it reaffirms the company's public trading status and transparency, which is fundamental for liquidity and investor confidence in their holdings.

Why It Matters

This filing confirms NewAmsterdam Pharma's continued compliance with SEC regulations, ensuring transparency and maintaining its public trading status for investors.

Risk Assessment

Risk Level: low — This 8-K is a routine compliance filing and does not indicate any new financial or operational risks for the company.

Analyst Insight

A smart investor would view this as a routine compliance update, confirming the company's operational status as a publicly traded entity. No immediate action is required based on this filing alone, but it reinforces the transparency expected from a listed company.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the purpose of NewAmsterdam Pharma Company N.V.'s 8-K filing on January 22, 2024?

The 8-K filing by NewAmsterdam Pharma Company N.V. on January 22, 2024, primarily serves as a Regulation FD Disclosure and to report on Financial Statements and Exhibits, confirming the registration of its Ordinary Shares and Warrants to Purchase Ordinary Shares pursuant to Section 12(b) of the Securities Exchange Act of 1934.

What specific securities of NewAmsterdam Pharma Company N.V. are mentioned as registered in this filing?

The filing specifically mentions that 'Ordinary Shares, nominal value €0.12 per share' and 'Warrants to Purchase Ordinary Shares' are registered pursuant to Section 12(b) of the Act.

What is the nominal value of NewAmsterdam Pharma Company N.V.'s Ordinary Shares, as stated in the filing?

The filing states that the Ordinary Shares have a nominal value of '€0.12 per share'.

What is the Commission File Number for NewAmsterdam Pharma Company N.V. according to this 8-K?

The Commission File Number for NewAmsterdam Pharma Company N.V. is '001-41562', as stated in the filing.

Where are NewAmsterdam Pharma Company N.V.'s principal executive offices located?

The principal executive offices of NewAmsterdam Pharma Company N.V. are located at 'Gooimeer 2-35, Naarden, The Netherlands, 1411 DC', according to the filing.

Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-01-22 08:01:09

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 22, 2024, NewAmsterdam Pharma Company N.V. (the "Company") posted an updated corporate investor presentation on its website (https://www.newamsterdampharma.com/). A copy of the corporate investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained on, or that can be accessed from, the Company's website is not incorporated into, and does not constitute a part of, this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 NewAmsterdam Pharma Company N.V. Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: January 22, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing